Efficacy of Prophylactic Anti-VEGF in Preventing Radiation Retinopathy: A Systematic Review and Meta-Analysis

References

• Melia M, Moy CS, Reynolds SM, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Arch Ophthalmol. 2006;124(2):226–238.
   PubMed Web of Science ®Google Scholar
• Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye. 2013;27(2):163–171. doi:10.1038/eye.2012.249
   PubMed Web of Science ®Google Scholar
• Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. Ophthalmology. 2001;108(2):348–366.
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol. 2007;125(6):751–756. doi:10.1001/archopht.125.6.751
   PubMedGoogle Scholar
• Finger PT. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol. 2007;143(2):335–338. doi:10.1016/j.ajo.2006.09.014
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin KJ, Semenova EA. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study. Eur J Ophthalmol. 2015;26(1):60–66. doi:10.5301/ejo.5000670
   PubMed Web of Science ®Google Scholar
• Shields CL, Say EA, Samara WA, Khoo CT, Mashayekhi A, Shields JA. Optical coherence tomography angiography of the macula after plaque radiotherapy of choroidal melanoma: comparison of irradiated versus nonirradiated eyes in 65 patients. Retina. 2016;36(8):1493–1505. doi:10.1097/IAE.0000000000001021
   PubMed Web of Science ®Google Scholar
• Skalet AH, Liu L, Binder C, et al. Longitudinal detection of radiation-induced peripapillary and macular retinal capillary ischemia using OCT angiography. Ophthalmol Retina. 2020;4(3):320–326. doi:10.1016/j.oret.2019.10.001
   PubMedGoogle Scholar
• Fam A, Tomar AS, Finger PT. OCT-A evaluation of radiation vasculopathy following slotted plaque brachytherapy. Eur J Ophthalmol. 2022;32(4):2459–2568. doi:10.1177/11206721211044339
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin KJ, Yu GP. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol. 2010;149(4):608–615. doi:10.1016/j.ajo.2009.11.006
   PubMed Web of Science ®Google Scholar
• Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000;84(9):1068–1070. doi:10.1136/bjo.84.9.1068
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Joussen AM, Lehmacher W, Hilgers RD, Kirchhof B. Is significant relevant? Validity and patient benefit of randomized controlled clinical trials on age-related macular degeneration. Surv Ophthalmol. 2007;52(3):266–278. doi:10.1016/j.survophthal.2007.02.010
   PubMed Web of Science ®Google Scholar
• Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30(7):1046–1050. doi:10.1097/IAE.0b013e3181d87e04
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• Yang X, Dalvin LA, Mazloumi M, et al. Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients. Clin Exp Ophthalmol. 2020;48(5):610–623. doi:10.1111/ceo.13758
   PubMed Web of Science ®Google Scholar
• Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES. Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma (An American ophthalmological society thesis). Trans Am Ophthalmol Soc. 2016;114.
   Google Scholar
• Shah SU, Shields CL, Bianciotto CG, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121(1):269–275. doi:10.1016/j.ophtha.2013.08.039
   PubMed Web of Science ®Google Scholar
• Powell BE, Finger PT. Anti–VEGF therapy immediately after plaque radiation therapy prevents or delays radiation maculopathy. Ophthalmol Retina. 2020;4(5):547–550. doi:10.1016/j.oret.2020.01.010
   PubMedGoogle Scholar
• Shields CL, Dalvin LA, Chang M, et al. Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma: comparison with nonrandomized historical control individuals. JAMA Ophthalmol. 2020;138(2):136–146. doi:10.1001/jamaophthalmol.2019.5132
   PubMed Web of Science ®Google Scholar
• Fallico M, Chronopoulos A, Schutz JS, Reibaldi M. Treatment of radiation maculopathy and radiation-induced macular edema: a systematic review. Surv Ophthalmol. 2021;66(3):441–460. doi:10.1016/j.survophthal.2020.08.007
   PubMed Web of Science ®Google Scholar
• Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys. 2008;70(4):974–977. doi:10.1016/j.ijrobp.2007.11.045
   PubMed Web of Science ®Google Scholar
• Finger PT, Chin KJ. Intravitreous ranibizumab (Lucentis) for radiation maculopathy. Arch Ophthalmol. 2010;128(2):249–252. doi:10.1001/archophthalmol.2009.376
   PubMedGoogle Scholar
• Finger PT, Chin KJ. High-dose (2.0 mg) intravitreal ranibizumab for recalcitrant radiation retinopathy. Eur J Ophthalmol. 2013;23(6):850–856. doi:10.5301/ejo.5000333
   PubMed Web of Science ®Google Scholar
• Fallico M, Reibaldi M, Avitabile T, et al. Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1547–1554. doi:10.1007/s00417-019-04347-6
   PubMed Web of Science ®Google Scholar
• Murray TG, Latiff A, Villegas VM, Gold AS. Aflibercept for radiation maculopathy study: a prospective, randomized clinical study. Ophthalmol Retina. 2019;3(7):561–566. doi:10.1016/j.oret.2019.02.009
   PubMedGoogle Scholar
• Elnahry AG, Noureldine AM, Abdel-Kader AA, Sorour OA, Ramsey DJ. Optical coherence tomography angiography biomarkers predict anatomical response to bevacizumab in diabetic macular edema. Diabetes Metab Syndr Obes. 2022;15:395–405. doi:10.2147/DMSO.S351618
   PubMed Web of Science ®Google Scholar
• Matet A, Daruich A, Zografos L. Radiation maculopathy after proton beam therapy for uveal melanoma: optical coherence tomography angiography alterations influencing visual acuity. Invest Ophthalmol Vis Sci. 2017;58(10):3851–3861. doi:10.1167/iovs.17-22324
   PubMed Web of Science ®Google Scholar
• Cennamo G, Montorio D, Bernardo R, et al. Retinal vascular changes in radiation maculopathy after intravitreal ranibizumab by optical coherence tomography angiography. J Clin Med. 2020;9(6):1618. doi:10.3390/jcm9061618
   PubMed Web of Science ®Google Scholar